Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28282932 | 0.88 | ENO1 (0.33) | RAB9A | |
| SCHEMBL5403207 | 0.81 | PEPD (0.31) | — | |
| SCHEMBL28178861 | 0.75 | DPP4 (0.33) | — | |
| SCHEMBL5411613 | 0.74 | ELANE (0.34) | RAB9A | |
| SCHEMBL3275668 | 0.74 | PDK2 (0.36) | — | |
| SCHEMBL3332146 | 0.74 | TSHR (0.36) | — | |
| SCHEMBL5413986 | 0.74 | PREP (0.35) | — | |
| SCHEMBL4590560 | 0.72 | CNR2 (0.32) | — | |
| SCHEMBL20815559 | 0.71 | RAB9A (0.43) | RAB9A | |
| SCHEMBL3332688 | 0.70 | KDM4E (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| US-20060229254-A1 | Compounds having prolyl oligopeptidase inhibitory activity | ORION CORPORATION (FI) | 2006-10-12 | — | — | US | disclosed |
| EP-1581489-A2 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY | ORION CORPORATION (FI) | 2005-10-05 | — | — | EP | disclosed |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2005-01-27 | — | — | US | disclosed |
| WO-2004060862-A2 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY | ORION CORPORATION (FI) | 2004-07-22 | — | — | WO | disclosed |
| US-4626545-A | Amino acid derivatives as enzyme inhibitors | MERCK & CO., INC. (US) | 1986-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229254-A1 | Compounds having prolyl oligopeptidase inhibitory activity | PREP, DNPEP, IDE | RAB9A 1442/4885 |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | DNPEP, PREP, ANPEP | RAB9A 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.